Premier warns chemotherapy fill rates

Premier’s warning on chemotherapy fill rates is a supply-chain story before it becomes a bedside story. The company said hospital order-fill data for key oncology medicines had fallen far enough to signal a higher risk of shortage, particularly for infusion drugs that cancer centers use on fixed treatment schedules. Other industry trackers and hospital reports show the same pattern: several generic chemotherapy agents remain in active shortage, and some manufacturers have pushed expected resupply dates into late 2026 or 2027. The issue matters because oncology clinics do not buy “shortages” in the abstract — they buy doses, vial sizes and delivery windows. When those orders arrive short, pharmacists and oncologists have to decide whether to delay treatment, substitute another regimen or reserve supply for patients with the clearest expected benefit, according to hospital and trade reporting. (premierinc.com) ### What does Premier mean by a chemotherapy “fill rate”? Premier uses fill rate as a measure of how much of a hospital’s order is actually supplied. In this case, the company’s recent tracking showed reduced fill rates for cancer drugs including ifosfamide and cisplatin, which Premier said were warning signs of tightening supply rather than a resolved shortage event. (beckershospitalreview.com) Becker’s Hospital Review, citing Premier data, reported that hospitals and cancer clinics working with Premier recently received only 38% of their ifosfamide orders and about two-thirds of their cisplatin orders. Those figures matter because oncology pharmacies plan treatment around complete regimens, not partial shipments. (premierinc.com) ### Which chemotherapy drugs are under the most pressure? As of late July, Becker’s reported that cisplatin, carboplatin, oxaliplatin and ifosfamide remained in active shortage, citing updates posted by the American Society of Health-System Pharmacists. Those drugs are used across breast, lung, ovarian, testicular, bladder, and head and neck cancers. (beckershospitalreview.com) ASHP’s shortage center says drug shortages can compromise or delay medical procedures and increase the risk of medication errors. Premier has separately described oncology drugs as part of a broader shortage problem affecting essential generics and sterile injectables across hospital pharmacy. ### Why are these shortages happening again? Premier has framed the problem as structural: global manufacturing disruptions, consolidation among generic manufacturers, and limited visibility into sourcing and production. (beckershospitalreview.com) The company said those conditions create a supply chain that is “fragile by design,” especially for low-margin injectable generics. (ashp.org) Axios reported on July 1 that doctors were seeing new shortages of widely used generic cancer drugs, reviving fears of delays and rationing. Becker’s said manufacturers have repeatedly pushed back resupply estimates, with some carboplatin presentations now not expected to return until 2027. ### What does this look like inside a cancer center? Hospitals facing short shipments are being advised to count total on-hand supply before starting combination regimens and to build patient-specific alternatives around tumor type and kidney or liver function, according to Becker’s summary of shortage guidance. (premierinc.com) The same report said clinicians were being told that no single substitute can fully replace the drugs in shortage. (axios.com) Premier has said shortages force clinicians into suboptimal substitutions, delay care and strain already stretched clinical teams. In infusion settings, where schedules are tightly sequenced, even partial order fulfillment can ripple into chair time, pharmacy compounding and patient scheduling. (beckershospitalreview.com) ### What should readers watch next? Manufacturer timelines are now one of the clearest signals. Becker’s reported that some cisplatin presentations were expected back in August, while certain carboplatin vial sizes were projected for October, December or as late as March, and some products still had no estimated release date. (premierinc.com) ASHP’s current shortage bulletins remain the running public tracker for active shortages, and Premier’s hospital fill-rate data will show whether partial shipments improve before those manufacturer dates arrive. (ashp.org) (beckershospitalreview.com)